SG Americas Securities
AUPH icon

SG Americas Securities’s Aurinia Pharmaceuticals AUPH Stock Holding History

SG Americas Securities’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.68M Buy
180,960
+44,736
+33% +$654K ﹤0.01% 1263
2025
Q4 		$2.17M Buy
136,224
+55,903
+70% +$792K ﹤0.01% 1479
2025
Q3 		$888K Sell
80,321
-3,771
-4% -$41.2K ﹤0.01% 1573
2025
Q2 		$712K Buy
84,092
+38,849
+86% +$311K ﹤0.01% 1406
2025
Q1 		$364K Sell
45,243
-17,321
-28% -$140K ﹤0.01% 2042
2024
Q4 		$562K Sell
62,564
-485,163
-89% -$3.96M ﹤0.01% 1222
2024
Q3 		$4.01M Buy
547,727
+535,301
+4,308% +$3.32M 0.01% 487
2024
Q2 		$71K Sell
12,426
-1,764
-12% -$9.29K ﹤0.01% 2617
2024
Q1 		$71K Sell
14,190
-21,017
-60% -$143K ﹤0.01% 2652
2023
Q4 		$317K Buy
35,207
+14,025
+66% +$116K ﹤0.01% 1790
2023
Q3 		$165K Buy
+21,182
New +$207K ﹤0.01% 2421
2022
Q3 		– Sell
-22,126
Closed -$222K – 3178
2022
Q2 		$222K Sell
22,126
-779,071
-97% -$8.71M ﹤0.01% 2593
2022
Q1 		$9.92M Buy
801,197
+144,992
+22% +$2.24M 0.07% 220
2021
Q4 		$15M Buy
656,205
+245,417
+60% +$5.82M 0.08% 184
2021
Q3 		$9.09M Buy
410,788
+243,678
+146% +$3.87M 0.04% 299
2021
Q2 		$2.17M Buy
167,110
+94,378
+130% +$1.2M 0.01% 1078
2021
Q1 		$944K Buy
+72,732
New +$1.06M ﹤0.01% 1581
2020
Q1 		– Sell
-5,105
Closed -$103K – 3432
2019
Q4 		$103K Sell
5,105
-41,009
-89% -$378K ﹤0.01% 2944
2019
Q3 		$246K Buy
+46,114
New +$279K ﹤0.01% 2254
2017
Q1 		– Sell
-373,209
Closed -$784K – 3266
2016
Q4 		$784K Hold
373,209
– – 0.01% 1441
2016
Q3 		$1.12M Buy
+373,209
New +$1.01M 0.01% 1084

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SG Americas Securities's AUPH Position: Q1 2026 in Review

SG Americas Securities increased its Aurinia Pharmaceuticals (AUPH) stake by 33% in Q1 2026, buying an estimated $654K and bringing the position to 180,960 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

SG Americas Securities first reported a position in AUPH in Q3 2016 and has held it in 21 quarters since. The position peaked at $15M in Q4 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • SG Americas Securities held 180,960 shares of Aurinia Pharmaceuticals worth $2.68M as of Q1 2026.
  • SG Americas Securities bought 44,736 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $654K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1263 holding.
  • SG Americas Securities first reported a position in Aurinia Pharmaceuticals in Q3 2016 and has held it in 21 quarters since.
  • SG Americas Securities's Aurinia Pharmaceuticals position peaked at $15M in Q4 2021.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.